Alkermes Receives Complete Response Letter From US Food and Drug Administration for ALKS 5461 New Drug Application - PRNewswire

Submitted by Anonymous (not verified) on Fri, 02/01/2019 - 21:01

Alkermes Receives Complete Response Letter From US Food and Drug Administration for ALKS 5461 New Drug Application  PRNewswireDUBLIN, Feb. 1, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it received a Complete Response Letter (CRL) from the U.S. Food ...